Jan 11-22
News
Publications
AxoProtego Nonconfidential Slide Deck, Winter 2022
Published: 25 April 2022
Preventing Peripheral Neuropathy in Chemotherapy, Diabetes, and Other Conditions
Safety and efficacy of ethoxyquin (6-ethoxy-1,2-dihydro-2,2,4-trimethylquinoline) for all animal species5
Published: 03 March 2022
EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2015. Safety and efficacy of ethoxyquin (6‐ethoxy‐1,2‐dihydro‐2,2,4‐trimethylquinoline) for all animal species. EFSA Journal. 2015;13(11). doi:10.2903/j.efsa.2015.4272.
Development of EQ‑6, a Novel Analogue of Ethoxyquin to Prevent Chemotherapy‑Induced Peripheral Neuropathy
Published: 21 July 2021
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often dose-limiting side effect of many cancer drugs. Because the onset of neuronal injury is known, it is an ideal clinical target to develop neuroprotective strategies.
Ethoxyquin is neuroprotective and partially prevents somatic and autonomic neuropathy in db/db mouse model of type 2 diabetes
Published: 24 May 2021
Ethoxyquin (EQ), a quinolone-based antioxidant, has demonstrated neuroprotective properties against several neurotoxic drugs in a phenotypic screening and is shown to protect axons in animal models of chemotherapy-induced peripheral neuropathy.
CISION PR Newswire
Published: 27 July 2020
AxoProtego Therapeutics Announces Novel Investigational Agent for Chemotherapy-Induced Peripheral Neuropathy
Programmed axon degeneration: from mouse to mechanism to medicine
Published: 09 March 2020
"...new data have indicated the potential of these advances to alleviate a number of common disorders, including chemotherapy- induced and diabetic peripheral neuropathies, traumatic brain injury, and amyotrophic lateral sclerosis."
Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations
Published: 27 July 2018
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially dose-limiting side effect of neurotoxic chemotherapies. No therapies are available to prevent CIPN. The small number of positive randomized clinical trials (RCTs) evaluating preventive therapies for CIPN provide little guidance to inform the design of future trials. 3
Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity
Published: 28 June 2016
Abstract
Ethoxyquin was recently identified as a neuroprotective compound against toxic neuropathies and efficacy was demonstrated against paclitaxel-induced neurotoxicity in vivo. In this study we examined the efficacy of ethoxyquin in preventing neurotoxicity of cisplatin in rodent models of chemotherapy-induced peripheral neuropathy and explored its mechanism of action.6
Ethoxyquin Prevents Chemotherapy-Induced Neurotoxicity via Hsp90 Modulation
Published: December 2013
Objective: Peripheral neurotoxicity is a major dose-limiting side effect of many chemotherapeutic drugs. Currently there are no effective disease-modifying therapies for chemotherapy-induced peripheral neuropathies, but these side effects of chemotherapy are potentially ideal targets for development of neuroprotective therapies, because candidate drugs can be co- or preadministered before the injury to peripheral axons takes place. (To read more click view publication)
Development of a High-Throughput Screening Cancer Cell-Based Luciferase Refolding Assay for Identifying Hsp90 Inhibitors4
Published: 11 October 2013
Abstract
The 90 kDa heat-shock protein (Hsp90) and other cochaperones allow for proper folding of nascent or misfolded polypeptides. Cancer cells exploit these chaperones by maintaining the stability of mutated and misfolded oncoproteins and allowing them to evade proteosomal degradation.
Ethoxyquin: An Antioxidant Used in Animal Feed1
Published: 30 April 2013
Abstract
Ethoxyquin (EQ, 6-ethoxy-1,2-dihydro-2,2,4-trimethylquinoline) is widely used in animal feed in order to protect it against lipid peroxidation. EQ cannot be used in any food for human consumption (except spices, e.g., chili), but it can pass from feed to farmed fish, poultry, and eggs, so human beings can be exposed to this antioxidant.
Wiley / PubMed
Multi‐center assessment of the Total Neuropathy Score for chemotherapy‐induced peripheral neurotoxicity2
Published: 15 June 2006
Abstract
The aim of this multi-center study was to assess with reduced versions of the Total Neuropathy Score (TNS), the severity of chemotherapy-induced peripheral neurotoxicity (CIPN), and to compare the results with those obtained with common toxicity scales.
View Wiley Online Library publication » View PubMed publication »
Bibliography
1 Błaszczyk A, Augustyniak A, Skolimowski J. Ethoxyquin: An Antioxidant Used in Animal Feed. International Journal of Food Science. 2013;2013:1-12. doi:10.1155/2013/585931.
2 Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System. 2006;11(2):135-141. doi:10.1111/j.1085-9489.2006.00078.x.
3 Gewandter JS, Brell J, Cavaletti G, et al. Trial designs for chemotherapy-induced peripheral neuropathy prevention. Neurology. 2018;91(9):403-413. doi:10.1212/wnl.0000000000006083.
4 Sadikot T, Swink M, Eskew JD, et al. Development of a High-Throughput Screening Cancer Cell-Based Luciferase Refolding Assay for Identifying Hsp90 Inhibitors. ASSAY and Drug Development Technologies. 2013;11(8):478-488. doi:10.1089/adt.2012.498.
5 Safety and efficacy of ethoxyquin (6‐ethoxy‐1,2‐dihydro‐2,2,4‐trimethylquinoline) for all animal species. EFSA Journal. 2015;13(11). doi:10.2903/j.efsa.2015.4272.
7 Zhu J, Carozzi VA, Reed N, et al. Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity. Scientific Reports. 2016;6(1). doi:10.1038/srep28861.